Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Innovative Technology to Change Current Standard of Care for Bladder Cancer Patients
The company’s proprietary technology could change the way surgeons handle cystoscopy procedures by displaying white light and blue light images side-by-side on one screen The technology is primarily promoted as an imaging device for bladder cancer but has the potential to expand to other endoscopic procedures including laparoscopic, colorectal and thoracic Bladder cancer is the sixth most prevalent cancer in the United States, with 600,000 people fearing recurrence The global market for bladder cancer is estimated to grow to an estimated $4.71 billion by 2026 The current standard of care for bladder cancer is minimally invasive surgery (MIS)uses white light…